Targeted pharmacotherapy after somatic cancer mutation screening [version 1; referees: 1 approved]

Thomas M. Polasek; Karen L. Ambler; Hamish S. Scott; Michael Joseph Sorich; Peter A. Kaub; Andrew Rowland; Michael D. Wiese; Ganessan Kichenadasse

doi:10.12688/F1000RESEARCH.9040.1

Targeted pharmacotherapy after somatic cancer mutation screening [version 1; referees: 1 approved]

Thomas M. Polasek, Karen L. Ambler, Hamish S. Scott, Michael Joseph Sorich, Peter A. Kaub, Andrew Rowland, Michael D. Wiese, Ganessan Kichenadasse

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

Many patients with solid tumours are treated with targeted pharmacotherapy based on the results of genetic testing ('precision medicine'). This study investigated the use of targeted drugs after OncoFOCUS™+KIT screening in patients with malignant melanoma, non-small cell lung cancer and metastatic colorectal cancer, and then audited the results against the National Comprehensive Cancer Network (NCCN) guidelines. Patients who were not indicated for targeted pharmacotherapy did not receive such treatment (99%, 100/101). Of the patients indicated for targeted drugs, 79% (33/42) received treatment according to NCCN guidelines. In 48% (20/42) of these patients the results from OncoFOCUS™+KIT screening were required for targeted drug selection. This study highlights the growing importance of precision medicine approaches in directing pharmacotherapy in medical oncology.

Original language	English
Article number	1551
Journal	F1000Research
Volume	5
DOIs	https://doi.org/10.12688/F1000RESEARCH.9040.1
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.12688/F1000RESEARCH.9040.1

Cite this

@article{d7eb0a9521154c2abb07a745bdf270c2,

title = "Targeted pharmacotherapy after somatic cancer mutation screening [version 1; referees: 1 approved]",

abstract = "Many patients with solid tumours are treated with targeted pharmacotherapy based on the results of genetic testing ('precision medicine'). This study investigated the use of targeted drugs after OncoFOCUS{\texttrademark}+KIT screening in patients with malignant melanoma, non-small cell lung cancer and metastatic colorectal cancer, and then audited the results against the National Comprehensive Cancer Network (NCCN) guidelines. Patients who were not indicated for targeted pharmacotherapy did not receive such treatment (99%, 100/101). Of the patients indicated for targeted drugs, 79% (33/42) received treatment according to NCCN guidelines. In 48% (20/42) of these patients the results from OncoFOCUS{\texttrademark}+KIT screening were required for targeted drug selection. This study highlights the growing importance of precision medicine approaches in directing pharmacotherapy in medical oncology.",

author = "Polasek, {Thomas M.} and Ambler, {Karen L.} and Scott, {Hamish S.} and Sorich, {Michael Joseph} and Kaub, {Peter A.} and Andrew Rowland and Wiese, {Michael D.} and Ganessan Kichenadasse",

year = "2016",

doi = "10.12688/F1000RESEARCH.9040.1",

language = "English",

volume = "5",

journal = "F1000Research",

issn = "2046-1402",

publisher = "F1000 Research Ltd (Science Navigation Group)",

}

TY - JOUR

T1 - Targeted pharmacotherapy after somatic cancer mutation screening [version 1; referees: 1 approved]

AU - Polasek, Thomas M.

AU - Ambler, Karen L.

AU - Scott, Hamish S.

AU - Sorich, Michael Joseph

AU - Kaub, Peter A.

AU - Rowland, Andrew

AU - Wiese, Michael D.

AU - Kichenadasse, Ganessan

PY - 2016

Y1 - 2016

N2 - Many patients with solid tumours are treated with targeted pharmacotherapy based on the results of genetic testing ('precision medicine'). This study investigated the use of targeted drugs after OncoFOCUS™+KIT screening in patients with malignant melanoma, non-small cell lung cancer and metastatic colorectal cancer, and then audited the results against the National Comprehensive Cancer Network (NCCN) guidelines. Patients who were not indicated for targeted pharmacotherapy did not receive such treatment (99%, 100/101). Of the patients indicated for targeted drugs, 79% (33/42) received treatment according to NCCN guidelines. In 48% (20/42) of these patients the results from OncoFOCUS™+KIT screening were required for targeted drug selection. This study highlights the growing importance of precision medicine approaches in directing pharmacotherapy in medical oncology.

AB - Many patients with solid tumours are treated with targeted pharmacotherapy based on the results of genetic testing ('precision medicine'). This study investigated the use of targeted drugs after OncoFOCUS™+KIT screening in patients with malignant melanoma, non-small cell lung cancer and metastatic colorectal cancer, and then audited the results against the National Comprehensive Cancer Network (NCCN) guidelines. Patients who were not indicated for targeted pharmacotherapy did not receive such treatment (99%, 100/101). Of the patients indicated for targeted drugs, 79% (33/42) received treatment according to NCCN guidelines. In 48% (20/42) of these patients the results from OncoFOCUS™+KIT screening were required for targeted drug selection. This study highlights the growing importance of precision medicine approaches in directing pharmacotherapy in medical oncology.

U2 - 10.12688/F1000RESEARCH.9040.1

DO - 10.12688/F1000RESEARCH.9040.1

M3 - Article

SN - 2046-1402

VL - 5

JO - F1000Research

JF - F1000Research

M1 - 1551

ER -

Targeted pharmacotherapy after somatic cancer mutation screening [version 1; referees: 1 approved]

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this